Pliant Therapeutics (Nasdaq: PLRX), a Californian biopharma focused on discovering and developing fibrosis drugs, closed up by more than a third on Monday.
On Sunday, the company had announced 12-week interim data from the 320mg dose group of INTEGRIS-IPF, a Phase IIa trial of bexotegrast in idiopathic pulmonary fibrosis (IPF).
"Unprecedented in clinical trials observed to date"This trial is evaluating bexotegrast at once-daily doses of 40mg, 80mg, 160mg, 320mg or placebo for 12 weeks in 119 patients with IPF.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze